What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Disease
Lymphoma, Internal medicine, Oncology, Immunology and Surgery are his primary areas of study.
Thomas M. Habermann focuses mostly in the field of Lymphoma, narrowing it down to matters related to B cell and, in some cases, Immunophenotyping.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His Oncology research integrates issues from Cancer, Neutropenia, Clinical endpoint, Follicular lymphoma and Chronic lymphocytic leukemia.
The concepts of his Immunology study are interwoven with issues in Single-nucleotide polymorphism and Risk factor.
His work focuses on many connections between Surgery and other disciplines, such as Incidence, that overlap with his field of interest in Testicular Involvement, Testicular Lymphoma and Combination chemotherapy.
His most cited work include:
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma (1052 citations)
- Association of perceived medical errors with resident distress and empathy: a prospective longitudinal study. (915 citations)
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing (726 citations)
What are the main themes of his work throughout his whole career to date?
Thomas M. Habermann spends much of his time researching Internal medicine, Lymphoma, Oncology, Diffuse large B-cell lymphoma and Surgery.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Immunology.
His studies examine the connections between Lymphoma and genetics, as well as such issues in Cohort, with regards to Prospective cohort study.
His study looks at the intersection of Oncology and topics like Single-nucleotide polymorphism with Candidate gene.
Thomas M. Habermann is interested in International Prognostic Index, which is a branch of Diffuse large B-cell lymphoma.
His work in Rituximab addresses subjects such as Vincristine, which are connected to disciplines such as Prednisone.
He most often published in these fields:
- Internal medicine (64.43%)
- Lymphoma (47.38%)
- Oncology (34.55%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (64.43%)
- Lymphoma (47.38%)
- Oncology (34.55%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Lymphoma, Oncology, Follicular lymphoma and Diffuse large B-cell lymphoma.
As part of his studies on Internal medicine, he often connects relevant areas like Gastroenterology.
Thomas M. Habermann studied Lymphoma and Biopsy that intersect with Positron emission tomography.
His Oncology research incorporates elements of International Prognostic Index, Randomized controlled trial, Toxicity and Transplantation.
In his study, which falls under the umbrella issue of Follicular lymphoma, Event free survival is strongly linked to PET-CT.
The various areas that Thomas M. Habermann examines in his Diffuse large B-cell lymphoma study include Cancer research, Organ function and Hazard ratio.
Between 2018 and 2021, his most popular works were:
- NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019. (45 citations)
- Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts (44 citations)
- ADDITION OF LENALIDOMIDE TO R‐CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG‐ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R‐CHOP (22 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
His primary areas of study are Internal medicine, Lymphoma, Oncology, Follicular lymphoma and Rituximab.
Internal medicine is closely attributed to Gastroenterology in his work.
His work on Diffuse large B-cell lymphoma as part of general Lymphoma study is frequently linked to Extramural, bridging the gap between disciplines.
His work on Progression-free survival is typically connected to In patient as part of general Oncology study, connecting several disciplines of science.
His Follicular lymphoma research is multidisciplinary, incorporating elements of Immunohistochemistry and International Prognostic Index.
His studies deal with areas such as Vincristine, Cyclophosphamide, Tolerability and Prednisone as well as Rituximab.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
